Antigen E from ragweed pollen has been modified by coupling about 8 of its 18 ε-amino groups with various alkoxypolyethylene glycols (ROPEG). These glycols include methoxy-PEGs of 2,000 and 5,000 daltons, n-lauryloxy-PEG of 1,200 daltons (BRIJ-35), and p-isooctylphenoxy-PEG of 3,300 daltons (Triton X-705). The immunogenic and immunosuppressive activities of these conjugates were tested in mice. They showed reduced immunogenicity for antigen E-specific IgE and IgG antibody responses although the BRIJ-35 conjugate showed only slightly decreased immunogenicity. The protein portion of the conjugate molecules appeared to contain the same antigenic determinants as in native antigen E. The alkoxypolyethyleneglycoxy portion of the conjugate molecules was found to be weakly immunogenic, since mice which had been immunized with such conjugates showed a transient weak IgE antibody response. All conjugates retained the immunosuppressive property of antigen E since the subcutaneous treatment of antigen E-sensitized mice with high doses of antigen E or of conjugate led to suppression of their specific IgE and IgG antibody levels.

This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.